{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:09:51Z","timestamp":1784408991738,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,22]]},"DOI":"10.7759\/cureus.84626","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T16:49:23Z","timestamp":1747932563000},"source":"Crossref","is-referenced-by-count":1,"title":["Successful Treatment of Adalimumab-Induced Pustular Psoriasis With Guselkumab in a Patient With Hidradenitis Suppurativa"],"prefix":"10.7759","author":[{"given":"Kostandin","family":"Valle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13139","article-title":"TNF-\u03b1 inhibitors reduce the pathological Th1-Th17\/Th2 imbalance in cutaneous mesenchymal stem cells of psoriasis patients","volume":"26","author":"Campanati A","year":"2017","unstructured":"Campanati A, Orciani M, Lazzarini R, et al.. TNF-\u03b1 inhibitors reduce the pathological Th1-Th17\/Th2 imbalance in cutaneous mesenchymal stem cells of psoriasis patients. Exp Dermatol. 2017, 26:319-24. 10.1111\/exd.13139","journal-title":"Exp Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.2.223","article-title":"Psoriasis and pustular dermatitis triggered by TNF-\u03b1 inhibitors in patients with rheumatologic conditions","volume":"143","author":"de Gannes GC","year":"2007","unstructured":"de Gannes GC, Ghoreishi M, Pope J, et al.. Psoriasis and pustular dermatitis triggered by TNF-\u03b1 inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007, 143:223-31. 10.1001\/archderm.143.2.223","journal-title":"Arch Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2808","article-title":"Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis","volume":"98","author":"Furue K","year":"2018","unstructured":"Furue K, Yamamura K, Tsuji G, et al.. Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol. 2018, 98:5-13. 10.2340\/00015555-2808","journal-title":"Acta Derm Venereol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.05.004","article-title":"Regulation of NF-\u03baB by TNF family cytokines","volume":"26","author":"Hayden MS","year":"2014","unstructured":"Hayden MS, Ghosh S. Regulation of NF-\u03baB by TNF family cytokines. Semin Immunol. 2014, 26:253-66. 10.1016\/j.smim.2014.05.004","journal-title":"Semin Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2256905","article-title":"Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa","volume":"34","author":"Vignoli CA","year":"2023","unstructured":"Vignoli CA, Gargiulo L, Sanna F, Narcisi A, Costanzo A. Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa. J Dermatolog Treat. 2023, 34:2256905. 10.1080\/09546634.2023.2256905","journal-title":"J Dermatolog Treat"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad C","year":"2018","unstructured":"Conrad C, Di Domizio J, Mylonas A, et al.. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018, 9:25. 10.1038\/s41467-017-02466-4","journal-title":"Nat Commun"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases","volume":"20","author":"Ko JM","year":"2009","unstructured":"Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009, 20:100-8. 10.1080\/09546630802441234","journal-title":"J Dermatolog Treat"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2014.47827","article-title":"Tumor necrosis factor inhibitors - state of knowledge","volume":"10","author":"Lis K","year":"2014","unstructured":"Lis K, Kuzawi\u0144ska O, Ba\u0142kowiec-Iskra E. Tumor necrosis factor inhibitors - state of knowledge. Arch Med Sci. 2014, 10:1175-85. 10.5114\/aoms.2014.47827","journal-title":"Arch Med Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222969","article-title":"Interleukin (IL)-17\/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses","volume":"15","author":"Mercurio L","year":"2020","unstructured":"Mercurio L, Failla CM, Capriotti L, et al.. Interleukin (IL)-17\/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses. PLoS One. 2020, 15:e0222969. 10.1371\/journal.pone.0222969","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1208817","article-title":"Hidradenitis suppurativa and psoriasis: the odd couple","volume":"10","author":"Macca L","year":"2023","unstructured":"Macca L, Li Pomi F, Ingrasciotta Y, Morrone P, Trifir\u00f2 G, Guarneri C. Hidradenitis suppurativa and psoriasis: the odd couple. Front Med (Lausanne). 2023, 10:1208817. 10.3389\/fmed.2023.1208817","journal-title":"Front Med (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach C","year":"2011","unstructured":"Schlapbach C, H\u00e4nni T, Yawalkar N, Hunger RE. Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011, 65:790-8. 10.1016\/j.jaad.2010.07.010","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot \u00c9","year":"2016","unstructured":"Toussirot \u00c9, Aubin F. Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016, 2:e000239. 10.1136\/rmdopen-2015-000239","journal-title":"RMD Open"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13699","article-title":"Generalized pustular psoriasis - a model disease for specific targeted immunotherapy, systematic review","volume":"27","author":"Boehner A","year":"2018","unstructured":"Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis - a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018, 27:1067-77. 10.1111\/exd.13699","journal-title":"Exp Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51405","article-title":"Guselkumab, a novel monoclonal antibody inhibitor of the p19 subunit of IL-23, for psoriatic arthritis and plaque psoriasis: a review of its mechanism, use, and clinical effectiveness","volume":"15","author":"Kerut CK","year":"2023","unstructured":"Kerut CK, Wagner MJ, Daniel CP, et al.. Guselkumab, a novel monoclonal antibody inhibitor of the p19 subunit of IL-23, for psoriatic arthritis and plaque psoriasis: a review of its mechanism, use, and clinical effectiveness. Cureus. 2023, 15:e51405. 10.7759\/cureus.51405","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.4846","article-title":"Risk of paradoxical eczema in patients receiving biologics for psoriasis","volume":"160","author":"Al-Janabi A","year":"2024","unstructured":"Al-Janabi A, Alabas OA, Yiu ZZ, et al.. Risk of paradoxical eczema in patients receiving biologics for psoriasis. JAMA Dermatol. 2024, 160:71-9. 10.1001\/jamadermatol.2023.4846","journal-title":"JAMA Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2023.06.013","article-title":"The effectiveness of guselkumab in patients with hidradenitis suppurativa under clinical practice conditions: a Spanish multicentre retrospective study","volume":"114","author":"Rivera-D\u00edaz R","year":"2023","unstructured":"Rivera-D\u00edaz R, Pozo T, Alfageme F, et al.. The effectiveness of guselkumab in patients with hidradenitis suppurativa under clinical practice conditions: a Spanish multicentre retrospective study. Actas Dermosifiliogr. 2023, 114:755-62. 10.1016\/j.ad.2023.06.013","journal-title":"Actas Dermosifiliogr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/368272-successful-treatment-of-adalimumab-induced-pustular-psoriasis-with-guselkumab-in-a-patient-with-hidradenitis-suppurativa","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T16:49:24Z","timestamp":1747932564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/368272-successful-treatment-of-adalimumab-induced-pustular-psoriasis-with-guselkumab-in-a-patient-with-hidradenitis-suppurativa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.84626","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,22]]}}}